Haemonetics Corp
Research Haemonetics Corp (HAE) on Bullrun: valuation model: 28.4% overvalued, market cap USD 4.93B, P/E 52.8. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerHAE
- ExchangeNYSE
- CountryUnited States
- SectorHealthcare
- IndustryMedical Devices
- CurrencyUSD
- Valuation signal28.4% overvalued
- Market capUSD 4.93B
- P/E52.8
- Financial periodFY2026
- RevenueUSD 1.33B
- Revenue growth-2.0%
- Net incomeUSD 97.31M
- Free cash flowUSD 260.44M
- Gross margin59.0%
Valuation Snapshot
Bullrun's latest valuation model marks Haemonetics Corp as 28.4% overvalued; latest market cap is USD 4.93B; P/E is 52.8.
Peer valuation comparison
Latest P/E is 52.83x versus a Healthcare sector median of 24.46x (116.0% above).
Latest P/E is 52.83x versus a United States median of 24.87x (112.5% above).
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2026 | USD 1.33B | USD 97.31M | USD 260.44M | 59.0% | 2.05 | USD 245.44M | USD 1.22B | USD 796.32M |
| FY2025 | USD 1.36B | USD 167.68M | USD 142.45M | 55.0% | 3.31 | USD 306.76M | USD 1.22B | USD 820.84M |
| FY2024 | USD 1.31B | USD 117.56M | USD 143.63M | 52.8% | 2.29 | USD 178.80M | USD 807.79M | USD 959.96M |
| FY2023 | USD 1.17B | USD 115.40M | USD 81.73M | 52.6% | 2.24 | USD 284.47M | USD 765.89M | USD 818.00M |
| FY2022 | USD 993.20M | USD 43.38M | USD 75.75M | 50.9% | 0.84 | USD 259.50M | USD 773.59M | USD 749.42M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 4.93B | 52.8 | n/a | n/a |
| 2025 | 2025-12-31 | USD 3.75B | 22.0 | n/a | n/a |
| 2024 | 2024-12-31 | USD 3.92B | 30.7 | n/a | n/a |
| 2023 | 2023-12-29 | USD 4.34B | 34.2 | n/a | n/a |
| 2022 | 2022-12-30 | USD 3.98B | 47.1 | n/a | n/a |
| 2021 | 2021-12-31 | USD 2.71B | 120.5 | n/a | n/a |
About Haemonetics Corp
Haemonetics Corporation, a medical technology company, provides a suite of hospital technologies solutions. The company operates through Plasma, Blood Center, and Hospital segments. It provides automated plasma collection systems, donor management software, and supporting software solutions, such as NexSys PCS plasmapheresis equipment system and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain;
Related stock research
Other Healthcare stocks
Frequently asked questions
Is Haemonetics Corp overvalued or undervalued?
Bullrun's valuation model currently marks Haemonetics Corp as 28.4% overvalued.
What is Haemonetics Corp's market cap?
Haemonetics Corp's market capitalization is USD 4.93B.
What is Haemonetics Corp's P/E ratio?
Haemonetics Corp's price-to-earnings (P/E) ratio is 52.8.
What does Haemonetics Corp do?
Haemonetics Corporation, a medical technology company, provides a suite of hospital technologies solutions. The company operates through Plasma, Blood Center, and Hospital segments. It provides automated plasma collection systems, donor management software, and supporting software solutions, such as NexSys PCS plasmapheresis equipment system and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 tools.